Oriola Corporation Stock Exchange Release, Inside information 11 November 2026 at 6:15 p.m. EET
Oriola Corporation revises its outlook for 2026. The fourth quarter result is not expected to be sufficient to reach the current full year guidance.
This is due to higher-than-expected operating expenses in October, mainly driven by disturbances in the Swedish supply chain operations.
New outlook for 2026:
For 2026, Oriola expects adjusted EBITDA to be at the same level as or increase from the previous year (2025: EUR 35.1 million).
The revised outlook reflects expected sales growth in both segments and the positive impact of new distribution partnerships in the fourth quarter.
Previous outlook for 2026 published on 25 February 2026:
In 2026, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics.
The uncertainty in the geopolitical environment remains, and the availability issues of certain pharmaceuticals are expected to continue. Typically, in economic uncertainty, consumers tend to shift purchases of everyday health and wellness products toward low-price categories.
For 2026, Oriola expects the adjusted EBITDA to increase from the previous year (2025: EUR 35.1 million). The expectation of improved adjusted EBITDA is based on growing markets and strategy execution.
Next financial report:
Oriola publishes its Financial Statements Release for 2026 on 23 February 2027. The silent period preceding the publication begins on 11 January 2027.
Further information:
Mats Danielsson
CFO
tel. +358 50 394 8575
e-mail: mats.danielsson@oriola.com
Distribution:
Nasdaq Helsinki Ltd
Key media